Kurt Huber
University of Debrecen
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Kurt Huber.
Open Heart | 2016
Miklos Rohla; Heinz Haberfeld; Helmut Sinzinger; Harald Kritz; Maximilian Tscharre; Matthias K. Freynhofer; Kurt Huber; Thomas W. Weiss
Background Early identification and treatment of cardiovascular risk factors (CVRFs) is essential to prevent excess morbidity, mortality and healthcare-related costs. We sought to investigate whether an active screening programme at pharmacies could identify a significant proportion of patients with previously undetected CVRFs. Methods and results Between April and July 2013, 184 pharmacies in Lower Austria enrolled a total of 6800 participants, in whom body mass index (BMI), blood pressure (BP), total cholesterol and blood glucose were measured. Mean age was 58±17u2005years and 67.8% were women. 21% of men and 16% of women had a BMI≥30u2005kg/m2. The crude prevalence of diabetes mellitus (DM) was 7%, hypercholesterolaemia was identified in 57%, and 44% had elevated BP. Among fasting individuals (n=1814), DM was found in 18%. In total, 30% were confronted with a CVRF they were previously unaware of, and pharmacists recommended 45% of all participants to actively consult a physician. A first-time diagnosis of a CVRF was most frequent in the age groups between 25 and 64 (32% of participants). Conclusions This pharmacy-based approach for cardiovascular risk screening found similar overall prevalences of CVRFs as reported by national surveys, but revealed underdiagnoses, particularly in lower age groups. A previously unknown CVRF was identified in every third individual, frequently prompting the pharmacists to recommend the consultation of a physician. An active screening approach at pharmacies might therefore serve as an effective alternative to the public preventive medical examination, particularly in younger age groups.
CME | 2012
Thomas Höchtl; Serdar Farhan; Kurt Huber
ZusammenfassungAntikoagulanzien werden standardmäßig bei Patienten mit akutem Koronarsyndrom oder Vorhofflimmern eingesetzt. In den letzten Jahren wurden zahlreiche neue Substanzen entwickelt und in klinischen Studien überprüft. Das Paradigma lautet dabei, dass diese Neuentwicklungen nicht nur die ischämischen oder thromboembolischen Ereignisse reduzieren sollen. Vielmehr soll vor allem die Rate an Blutungskomplikationen sinken. Die wichtigsten Substanzen sind derzeit Bivalirudin, Fondaparinux, Rivaroxaban, Apixaban und Dabigatran. Aktuell sind im deutschsprachigen Raum Rivaroxaban und Dabigatran für die Prävention von Schlaganfällen und systemischen Embolien bei nichtvalvulärem Vorhofflimmern zugelassen.
Archive | 2014
Konstantinos Spargias; Mariann Gyöngyösi; Rayyan Hemetsberger; Anikó Pósa; Noemi Pavo; Imre Pavo; Kurt Huber; Zsolt Petrasi; Örs Petneházy; Rembert Pogge von Strandmann; Jeffrey Park; Dietmar Glogar; Gerald Maurer; Nalini M. Rajamannan
Balloon aortic valvuloplasty (BAV) was introduced in 1986 as an alternative non- surgical therapeutic option in elderly and high-risk patients with aortic stenosis [1]. It generates small to moderate increase in the effective aortic valve area (AVA) and decline in the transvalvular pressure gradient (by average 50 %) which results in early symptomatic improvements in the majority of patients [2–5]. Nonetheless, clinical data demonstrates restenosis rates of the aortic valve occurring up to 83 % observed at 6 months and is almost universal within 1 year after the procedure [3, 6, 7]. Restenosis promptly revokes the improvement in symptoms and quality of life, which is so much valued especially in the elderly population with multiple comorbidities and limited life expectancy. The initial enthusiasm about BAV led to its more liberal use in high-risk patients but registry data indicated that it does not alter the natural history of aortic stenosis [8].
American Heart Journal | 2007
Tibor Szük; Mariann Gyöngyösi; Nóra Homoródi; Eva Kristof; Csaba Kiraly; István Édes; Andrea Facskó; Noemi Pavo; Gottfried Sodeck; Christoph Strehblow; Serdar Farhan; Gerald Maurer; Dietmar Glogar; Hans Domanovits; Kurt Huber
Archive | 2015
Takeshi Kamijo; Masahiko Kinoshita; Takayoshi Tsutamoto; Naoko Mabuchi; Mariann Gyöngyösi; Georg Geyer; Johann Wojta; Kurt Huber; Rudolf Jarai; Nelly Iordanova; Róbert Járai; Annamaria Raffetseder; Wolfgang Woloszczuk
/data/revues/00029149/unassign/S0002914914000381/ | 2014
Ioannis Tentzeris; Miklos Rohla; Rudolf Jarai; Serdar Farhan; Matthias K. Freynhofer; Gerhard Unger; Michael Nürnberg; Alexander Geppert; Emil Wessely; Johann Wojta; Kurt Huber
Archive | 2013
Gerald Maurer; Kurt Huber; Peter Valent; Wolfgang R. Sperr; Gerhard Fritsch; Dieter Printz; Bernd R. Binder; Georg Schatzl; Joerg Zwirner; Johann Wojta; Christoph Kaun; Gerlinde Zorn; Minoo Ghannadan; Alexander W. Hauswirth
Archive | 2012
Fernando Alfonso; Adam Timmis; Fausto Pinto; Giuseppe Ambrosio; Hugo Ector; Loizos Antoniades; Mansoor Ahmad; Eduard Apetrei; Kaduo Arai; Jean-Yves Artigou; Michael Aschermann; Michael Böhm; Leonardo Bolognese; Raffaele Bugiardini; Ariel Cohen; István Édes; Joseph Elias; Javier Galeano; Habib Haouala; Magda Heras; Christer Höglund; Kurt Huber; Ivan Hulín; Mario Ivanusa; Chi-Tai Kuo; Chu-Pak Lau; Victor A. Lyusov; Manlio F. Márquez; Izet Masic; Luiz Felipe
/data/revues/00028703/v144i3/S0002870302001084/ | 2011
W. Speidl; Senta Graf; Stefan Hornykewycz; Mariam Nikfardjam; Alexander Niessner; Gerlinde Zorn; Johann Wojta; Kurt Huber
Archive | 2010
Georg Grimm; Heinz Sochor; Dietmar Glogar; Innere Medizin; Josef Aichinger; Helmut Brussee; Burkert Pieske; Günter Heyer; Heinz Koller; H. Krappinger; Krankenhaus Rudolfstiftung; Franz Weidinger; Werner Benzer; Georg Gaul; Ana Mar oa; Gerhard Bonner; Helmut D. Glogar; Norbert Muzika; Hubert Wallner; Martin Klicpera; Max Pichler; Gerald Zenker; Klaus Kaspar; Kurt Huber; Peter Siostrzonek; Dieter Brandt; G. Obermayer; Karl Silberbauer; Bernd Eber; Krankenhaus der Stadt Krems